<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062398</url>
  </required_header>
  <id_info>
    <org_study_id>CP-02-001</org_study_id>
    <nct_id>NCT02062398</nct_id>
  </id_info>
  <brief_title>BlueWind Medical Reprieve System for the Treatment of PNP</brief_title>
  <acronym>PNP</acronym>
  <official_title>Safety and Performance of the BlueWind Medical Reprieve System for the Treatment of Patients With Peripheral Neuropathic Pain (PNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlueWind Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlueWind Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will evaluate the safety and performance of the BlueWind Medical Reprieve
      System for the treatment of Chronic Painful Peripheral Neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BlueWind Reprieve system is a neurostimulator consisting of an Implant and external
      components.

      The system is intended for home care use. The chronic pain treatment is achieved by an
      electrical stimulation of peripheral nerve fibers. The stimulation is set so that it
      generates paresthesia in the stimulated area (e.g. foot), reducing the pain sensation and
      improving the quality of life for the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of System and/or Procedure Related Serious Adverse Events (SAEs).</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of system and/or procedure related serious adverse events (SAEs) throughout the entire study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Assessment by Visual Analogue Scale (VAS) as Compared to Baseline at 6 Months Post Activation</measure>
    <time_frame>1 Month, 3 Months, and 6 months post system activation</time_frame>
    <description>VAS score assessment at baseline and follow up visits was performed in two ways;
Pain Diary VAS score- the analysis was based on the pain diary, processing the average daily VAS scores over seven consecutive days.
Point VAS score- the analysis was based on the VAS score measurement recorded during the baseline visit and following 30 minutes stimulation at all follow up visits.Pain assessment by Visual Analogue Scale (VAS) as compared to baseline, post system activation.
Visual Analogue Scale (VAS) for Pain Scores on a scale [0 - 10], higher values represent a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success 6 Months Post Activation</measure>
    <time_frame>1 Month, 3 Months, and 6 months post system activation</time_frame>
    <description>Clinical success at 6 months post activation was further assessed by:Short-form McGill pain questionnaire.
McGill pain questionnaire Scores on a scale Range [0-60] points, higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success 6 Months Post Activation</measure>
    <time_frame>6 months post activation</time_frame>
    <description>Clinical success is defined as the effect of the BlueWind Reprieve System on the treatment of the following symptoms compared to baseline:
- Pain related medication consumption/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success 6 Months Post Activation</measure>
    <time_frame>1 Month, 3 Months, and 6 months post system activation</time_frame>
    <description>Clinical success was further assessed by: Quality of life questionnaire (SF-36 Health Survey) SF-36 Health Survey Scores on a scale [0 - 100], higher values represent a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>The Reprieve system implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Reprieve System</intervention_name>
    <description>BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
    <arm_group_label>The Reprieve system implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent.

          2. Male or female aged 18 - 80.

          3. Patient agrees to attend all follow-up evaluations and is willing to completely and
             accurately fill out pain questionnaires.

          4. Diagnosis of chronic neuropathic pain due to peripheral neuropathy.

          5. Documented pain attributed to neuropathy for at least 6 months.

          6. Pain intensity with an average daily VAS score of at least 6, demonstrated by 2-3
             ratings per day across 7 days.

          7. Patient refractory to conservative treatments including pain medication, for at least
             6 months.

          8. Stable pain medication for at least 4 weeks prior to study enrollment.

        Exclusion Criteria:

          1. Previous participation in another study with any investigational drug or device within
             the past 90 days.

          2. Any active implant (cardiac or other).

          3. Any metal implant in the area of BlueWind device implantation site.

          4. Current pregnancy or attempting to get pregnant (female patient).

          5. Any clinically significant neurologic disorders (except PNP).

          6. Any clinically significant or unstable medical or psychiatric condition that would
             affect the patient's ability to participate in the study.

          7. Patients with severe or unstable cardiovascular, pulmonary, gastrointestinal,
             hematological, hepatic, renal or endocrine diseases.

          8. Severe peripheral vascular disease that may cause intermittent claudication or
             ischemic ulcers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Pierre Van Buyten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sint-Niklaas hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge - Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Niklaas Hospital</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>B-9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10 Military Clinical Hospital</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>5 85-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CenterMed Kraków Sp.z o.o.</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <results_first_submitted>November 13, 2018</results_first_submitted>
  <results_first_submitted_qc>December 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2019</results_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNP</keyword>
  <keyword>Stimulation</keyword>
  <keyword>Peripheral neurostimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>The Reprieve System Implantation</title>
          <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Implant removal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>The Reprieve System Implantation</title>
          <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" lower_limit="40" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pain measurement using Visual Analogue Scale</title>
          <description>Visual Analogue Scale for Pain 0 (no pain) - 10 (max pain) higher values represent a worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.58" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Incidence of System and/or Procedure Related Serious Adverse Events (SAEs).</title>
        <description>The incidence of system and/or procedure related serious adverse events (SAEs) throughout the entire study period</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>The Reprieve System Implantation</title>
            <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of System and/or Procedure Related Serious Adverse Events (SAEs).</title>
          <description>The incidence of system and/or procedure related serious adverse events (SAEs) throughout the entire study period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Assessment by Visual Analogue Scale (VAS) as Compared to Baseline at 6 Months Post Activation</title>
        <description>VAS score assessment at baseline and follow up visits was performed in two ways;
Pain Diary VAS score- the analysis was based on the pain diary, processing the average daily VAS scores over seven consecutive days.
Point VAS score- the analysis was based on the VAS score measurement recorded during the baseline visit and following 30 minutes stimulation at all follow up visits.Pain assessment by Visual Analogue Scale (VAS) as compared to baseline, post system activation.
Visual Analogue Scale (VAS) for Pain Scores on a scale [0 - 10], higher values represent a worse outcome.</description>
        <time_frame>1 Month, 3 Months, and 6 months post system activation</time_frame>
        <population>Out of the 13 treated patients, one device was explanted approximately after 3 weeks of treatment. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>The Reprieve System Implantation</title>
            <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment by Visual Analogue Scale (VAS) as Compared to Baseline at 6 Months Post Activation</title>
          <description>VAS score assessment at baseline and follow up visits was performed in two ways;
Pain Diary VAS score- the analysis was based on the pain diary, processing the average daily VAS scores over seven consecutive days.
Point VAS score- the analysis was based on the VAS score measurement recorded during the baseline visit and following 30 minutes stimulation at all follow up visits.Pain assessment by Visual Analogue Scale (VAS) as compared to baseline, post system activation.
Visual Analogue Scale (VAS) for Pain Scores on a scale [0 - 10], higher values represent a worse outcome.</description>
          <population>Out of the 13 treated patients, one device was explanted approximately after 3 weeks of treatment. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Diary VAS Score - 1M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Diary VAS score - 3M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Diary VAS Score - 6M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Point VAS Score - 1M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Point VAS score - 3M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Point VAS Score - 6M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success 6 Months Post Activation</title>
        <description>Clinical success at 6 months post activation was further assessed by:Short-form McGill pain questionnaire.
McGill pain questionnaire Scores on a scale Range [0-60] points, higher values represent a worse outcome.</description>
        <time_frame>1 Month, 3 Months, and 6 months post system activation</time_frame>
        <population>Only 12 out of 13 patients completed the study. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>The Reprieve System Implantation</title>
            <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success 6 Months Post Activation</title>
          <description>Clinical success at 6 months post activation was further assessed by:Short-form McGill pain questionnaire.
McGill pain questionnaire Scores on a scale Range [0-60] points, higher values represent a worse outcome.</description>
          <population>Only 12 out of 13 patients completed the study. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>McGill pain questionnaire - 1M post sys activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill pain questionnaire - 3M post sys activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill pain questionnaire - 6M post sys activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success 6 Months Post Activation</title>
        <description>Clinical success is defined as the effect of the BlueWind Reprieve System on the treatment of the following symptoms compared to baseline:
- Pain related medication consumption/day</description>
        <time_frame>6 months post activation</time_frame>
        <population>Only 12 out of 13 patients completed the study. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>The Reprieve System Implantation</title>
            <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success 6 Months Post Activation</title>
          <description>Clinical success is defined as the effect of the BlueWind Reprieve System on the treatment of the following symptoms compared to baseline:
- Pain related medication consumption/day</description>
          <population>Only 12 out of 13 patients completed the study. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>not consumed any pain related medication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>didn't change medication consumption</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Reduction in medication consumption</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success 6 Months Post Activation</title>
        <description>Clinical success was further assessed by: Quality of life questionnaire (SF-36 Health Survey) SF-36 Health Survey Scores on a scale [0 - 100], higher values represent a better outcome.</description>
        <time_frame>1 Month, 3 Months, and 6 months post system activation</time_frame>
        <population>Only 12 out of 13 patients completed the study. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>The Reprieve System Implantation</title>
            <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success 6 Months Post Activation</title>
          <description>Clinical success was further assessed by: Quality of life questionnaire (SF-36 Health Survey) SF-36 Health Survey Scores on a scale [0 - 100], higher values represent a better outcome.</description>
          <population>Only 12 out of 13 patients completed the study. Thus, safety analysis is given for 13 patients and the performance analysis report on 12 patients.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 Health Survey - 1M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 Health Survey - 3M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 Health Survey - 6M post system activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>The Reprieve System Implantation</title>
          <description>The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
The Reprieve System: BlueWind Medical neurostimulator for the treatment of neuropathic pain</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>low grade infection and delayed closure of surgical wound</sub_title>
                <description>The Reprieve implant was explanted approximately after 3 weeks of treatment.Patient was treated with antibiotics. The event terminated without further sequel and was classified as non-procedural related and its relationship to the device was unknown.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>implant site discolouration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritatation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Participating Institution and /or investigator may publish/present the results of the clinical investigation (&quot;publication&quot;) only upon prior written consent provided by BlueWind Medical Ltd.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amit Korner, VP Clinical Research</name_or_title>
      <organization>BlueWind Medical</organization>
      <phone>+972.74.7218905</phone>
      <email>amit.korner@bluewindmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

